Alamar Biosciences, Inc.
30.69USD
+0.9700 (+3.26%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ALMR.
Revenue
| (USD) | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| FY | — | — | 118.6M | 165.7M |
| Q1 | — | 13.1M | 26.0M | — |
| Q2 | — | 16.2M | 29.4M | — |
| Q3 | — | — | 30.2M | — |
| Q4 | — | — | 32.9M | — |
Revenue
| (USD) | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| FY | — | — | -1.10 | -.452 |
| Q1 | — | -.680 | -1.74 | — |
| Q2 | — | -.620 | -.220 | — |
| Q3 | — | — | -.187 | — |
| Q4 | — | — | -.185 | — |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
Debt level and coverage